Log in

Merus Stock Forecast, Price & News

-1.06 (-8.19 %)
(As of 09/21/2020 12:00 AM ET)
Today's Range
Now: $11.88
50-Day Range
MA: $12.27
52-Week Range
Now: $11.88
Volume80,035 shs
Average Volume103,535 shs
Market Capitalization$345.02 million
P/E RatioN/A
Dividend YieldN/A
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers. The company is also developing MCLA-117 that is in Phase I clinical trial for the treatment of patients with acute myeloid leukemia; and MCLA-158, which is in a Phase I clinical trial for treating metastatic colorectal cancer. In addition, its preclinical development stage bispecific antibody candidates include MCLA-145, which is being developed in collaboration with Incyte Corporation; and other preclinical candidates in various stages of development. Merus N.V. has collaboration with the Integral Molecular for discovering MAbs against structurally complex proteins; and Lipoparticles, virus-like particles displaying high concentrations of membrane proteins. The company was founded in 2003 and is headquartered in Utrecht, the Netherlands.
Read More
Merus logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.97 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:MRUS



Sales & Book Value

Annual Sales$31.13 million
Book Value$5.61 per share


Net Income$-55,150,000.00
Net Margins-243.85%


Market Cap$345.02 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
-1.06 (-8.19 %)
(As of 09/21/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MRUS News and Ratings via Email

Sign-up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Merus (NASDAQ:MRUS) Frequently Asked Questions

How has Merus' stock been impacted by Coronavirus (COVID-19)?

Merus' stock was trading at $14.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MRUS shares have decreased by 18.3% and is now trading at $11.88.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Merus?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Merus

When is Merus' next earnings date?

Merus is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Merus

How were Merus' earnings last quarter?

Merus NV (NASDAQ:MRUS) issued its quarterly earnings data on Thursday, August, 6th. The biotechnology company reported ($0.59) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.59). The biotechnology company had revenue of $6.67 million for the quarter, compared to analysts' expectations of $6.79 million. Merus had a negative return on equity of 66.84% and a negative net margin of 243.85%.
View Merus' earnings history

What price target have analysts set for MRUS?

3 brokerages have issued 1 year price objectives for Merus' stock. Their forecasts range from $16.00 to $23.00. On average, they expect Merus' stock price to reach $20.67 in the next year. This suggests a possible upside of 74.0% from the stock's current price.
View analysts' price targets for Merus

Are investors shorting Merus?

Merus saw a increase in short interest during the month of July. As of July 31st, there was short interest totaling 279,700 shares, an increase of 8.4% from the July 15th total of 258,100 shares. Based on an average trading volume of 118,400 shares, the days-to-cover ratio is currently 2.4 days. Currently, 1.5% of the shares of the stock are short sold.
View Merus' Short Interest

Who are some of Merus' key competitors?

What other stocks do shareholders of Merus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merus investors own include Pfizer (PFE), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Opko Health (OPK), Exelixis (EXEL), Fulcrum Therapeutics (FULC), Inovio Pharmaceuticals (INO), Intel (INTC), AT&T (T) and Aimmune Therapeutics (AIMT).

Who are Merus' key executives?

Merus' management team includes the following people:
  • Dr. Ton Logtenberg, Pres, CEO, Principal Financial Officer & Exec. Director (Age 61)
  • Dr. Hennie Hoogenboom Ph.D., Co-Founder and Scientific Advisor
  • Ms. Jillian Connell, VP of Investor Relations & Corp. Communications
  • Mr. John de Kruif Ph.D., CTO & Sr. VP (Age 55)
  • Mr. Mark Throsby Ph.D., Chief Scientific Officer & Exec. VP (Age 52)

When did Merus IPO?

(MRUS) raised $64 million in an initial public offering on Thursday, May 19th 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.

What is Merus' stock symbol?

Merus trades on the NASDAQ under the ticker symbol "MRUS."

Who are Merus' major shareholders?

Merus' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BVF Inc. IL (17.53%), Federated Hermes Inc. (8.40%), Sofinnova Investments Inc. (4.51%), Driehaus Capital Management LLC (2.83%), Artal Group S.A. (1.32%) and Platinum Investment Management Ltd. (0.66%). Company insiders that own Merus stock include Bvf Partners L P/Il, Mark Throsby and Value Fund L P Biotechnology.
View institutional ownership trends for Merus

Which major investors are selling Merus stock?

MRUS stock was sold by a variety of institutional investors in the last quarter, including Sofinnova Investments Inc., Driehaus Capital Management LLC, Artal Group S.A., Platinum Investment Management Ltd., Alps Advisors Inc., and Old West Investment Management LLC.
View insider buying and selling activity for Merus

Which major investors are buying Merus stock?

MRUS stock was acquired by a variety of institutional investors in the last quarter, including BVF Inc. IL, Federated Hermes Inc., California Public Employees Retirement System, Swiss National Bank, Two Sigma Advisers LP, Bank of New York Mellon Corp, PDT Partners LLC, and Athanor Capital LP. Company insiders that have bought Merus stock in the last two years include Bvf Partners L P/Il, and Value Fund L P Biotechnology.
View insider buying and selling activity for Merus

How do I buy shares of Merus?

Shares of MRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Merus' stock price today?

One share of MRUS stock can currently be purchased for approximately $11.88.

How big of a company is Merus?

Merus has a market capitalization of $345.02 million and generates $31.13 million in revenue each year. The biotechnology company earns $-55,150,000.00 in net income (profit) each year or ($2.33) on an earnings per share basis. Merus employs 98 workers across the globe.

What is Merus' official website?

The official website for Merus is www.merus.nl.

How can I contact Merus?

Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The biotechnology company can be reached via phone at 31-0-30-253-8800 or via email at [email protected]

This page was last updated on 9/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.